乳腺癌组织中Livin和Smac的表达及其临床意义

Expressions of Livin and Smac Proteins in Breast Cancer and Their Clinical Significance

目的:探讨Livin和Smac蛋白在乳腺癌组织和癌旁组织中的表达及其临床意义。方法:收集乳腺癌患者43例,采用免疫组织化学S-P法检测Livin及Smac在乳腺癌组织、癌旁组织中的表达情况,应用“检验、K-M法分析临床特征及生存情况。结果:Livin在乳腺癌组织中的阳性表达率为79.1%,癌旁组织中表达率为48.8%,差异有统计学意义(P<0.05);Smac在乳腺癌组织中的阳性表达率为74.4%,癌旁组织中表达率为93.0%,差异也有统计学意义(P<0.05)。Livin和Smac蛋白的表达均与乳腺癌的TNM分期及淋巴结转移情况相关,其差异有统计学意义(两组P<0.05),并且乳腺癌组织中Livin与Smac的表达情况呈负相关(P<0.05)。此外,Livin阴性组与阳性组中5年无病生存率分别为66.7%和23.5%,Livin阴性组比阳性组无病生存期有所延长(P<0.05),而Smac阴性组与阳性组的无病生存期差异无统计学意义(P>0.05)。结论:Livin,Smac在乳腺癌中的表达水平呈负相关,提示可能有某种机制在调节这两者的表达。另外丄ivin阴性组患者的5年无病生存期有所延长,提示该蛋白或可作为乳腺癌患者的预后指标,值得进一步研究。

Objective: To explore the expression and clinic-pathological characteristics of Livin and Smac in breast carcinoma tissue. Methods: S-P immunohistochemical staining was adopted to examine the expression of Livin and Smac;breast cancer samples ( n =43 ) were assembled from West China Hospital, Sichuan University. Results: The positive expression of Livin in breast cancer tissue was 79. 1 %, and it was 48. 8% in paracarcinoma tissue. The difference between the two groups was statistically significant ( P <0. 05 ). Meanwhile, the positive expression of Smac in breast cancer tissue was 74. 4%, and it was 93. 0% in paracarcinoma tissue. The difference between the two groups was statistically significant ( P < 0. 05 ). Livin protein expression in breast cancer was closely related to clinical stage and lymph node metastasis ( P < 0. 05 ). A negative correlation was found between the expression of Livin and that of Same in breast cancer ( P < 0. 05 ). The 5-year disease free survival ( DFS) of the Livin-negative group (66. 7%) was significantly longer than that of the Livin-positive group (23. 5%,P < 0. 05 ), while the 5-year DFS of the Smac-negative group and that of the Smac-positive group were not significantly different ( P > 0. 05 ). Conclusion: The expression level of Livin in breast cancer tissue is negatively related to the expression level of Smac in breast cancer tissue, indicating a negative correlation between these two proteins. Meanwhile, the 5 year DFS of Livin-negative patients is significantly longer than that of the Livin-positive patients. Therefore, Livin may be employed as a prognosis indicator for breast cancer patients.